Richard S Finn Selected Research

src-Family Kinases

11/2011	Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
8/2010	SRC: a century of science brought to the clinic.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard S Finn Research Topics

Disease

97	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 02/2009
65	Neoplasms (Cancer) 02/2024 - 12/2004
54	Breast Neoplasms (Breast Cancer) 01/2024 - 01/2003
11	Hypertension (High Blood Pressure) 12/2023 - 04/2011
9	Liver Neoplasms (Liver Cancer) 10/2023 - 01/2012
9	Neutropenia 01/2021 - 01/2015
8	Liver Diseases (Liver Disease) 03/2024 - 01/2018
8	Disease Progression 10/2023 - 09/2009
8	Fatigue 01/2021 - 04/2011
5	Cholangiocarcinoma 10/2019 - 04/2011
4	Fibrosis (Cirrhosis) 09/2023 - 01/2019
4	Infections 02/2023 - 07/2004
4	Triple Negative Breast Neoplasms 08/2015 - 11/2007
4	Diarrhea 03/2015 - 12/2008
3	Circulating Neoplastic Cells 01/2022 - 10/2020
3	Inflammation (Inflammations) 01/2022 - 01/2019
3	Febrile Neutropenia 01/2021 - 11/2016
3	Leukopenia 01/2019 - 03/2015
3	Exanthema (Rash) 02/2017 - 12/2008
3	Carcinogenesis 02/2016 - 02/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2013 - 07/2010
2	Hepatorenal Syndrome 12/2023 - 01/2019
2	Hepatitis 02/2023 - 01/2022
2	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 03/2011
2	Pain (Aches) 01/2021 - 01/2020
2	Back Pain (Backache) 01/2020 - 01/2015
2	Proteinuria 10/2019 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 12/2013
2	Hyponatremia 11/2014 - 10/2013
2	Stomach Neoplasms (Stomach Cancer) 04/2013 - 03/2010
2	Retinoblastoma (Glioblastoma, Retinal) 03/2011 - 01/2009

Drug/Important Bio-Agent (IBA)

36	Sorafenib (BAY 43-9006)FDA Link 03/2024 - 12/2010
30	palbociclibIBA 01/2024 - 01/2009
28	ErbB Receptors (EGF Receptor)IBA 01/2024 - 12/2008
20	Hormones (Hormone)IBA 11/2023 - 05/2013
16	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2013
14	Bevacizumab (Avastin)FDA Link 03/2024 - 02/2009
13	Estrogen ReceptorsIBA 01/2024 - 01/2009
12	Letrozole (Femara)FDA LinkGeneric 01/2024 - 01/2015
11	atezolizumabIBA 03/2024 - 01/2020
11	pembrolizumabIBA 12/2023 - 01/2018
11	RamucirumabIBA 12/2022 - 12/2013
11	Trastuzumab (Herceptin)FDA Link 02/2015 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 12/2008
10	Phosphotransferases (Kinase)IBA 02/2019 - 11/2007
9	lenvatinibIBA 03/2024 - 01/2018
9	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2022 - 10/2014
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2009
8	Lapatinib (GW572016)FDA Link 02/2014 - 12/2008
7	Tyrosine Kinase InhibitorsIBA 09/2023 - 12/2008
7	Cyclin-Dependent Kinase 4IBA 08/2022 - 01/2015
7	Monoclonal AntibodiesIBA 06/2019 - 01/2003
6	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2018
6	human ERBB2 proteinIBA 09/2023 - 12/2008
5	regorafenibIBA 02/2024 - 01/2017
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2023 - 01/2018
5	Phenobarbital (Luminal)FDA Link 11/2020 - 11/2007
5	Cyclin-Dependent Kinases (cdk Proteins)IBA 02/2019 - 01/2015
4	NivolumabIBA 02/2024 - 01/2018
4	AlbuminsIBA 10/2023 - 01/2021
4	Epidermal Growth Factor (EGF)IBA 03/2023 - 12/2004
4	Fetal Proteins (Fetoprotein)IBA 12/2022 - 01/2019
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2018 - 09/2012
4	brivanibIBA 11/2014 - 04/2011
4	Paclitaxel (Taxol)FDA LinkGeneric 11/2009 - 12/2008
3	BilirubinIBA 10/2023 - 04/2021
3	Gemcitabine FDA Link 01/2023 - 12/2014
3	Cyclin DIBA 01/2023 - 01/2009
3	Messenger RNA (mRNA)IBA 01/2022 - 12/2008
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 09/2012
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2014 - 03/2010
3	Dasatinib (BMS 354825)FDA Link 05/2013 - 11/2007
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2013 - 02/2009
2	durvalumabIBA 03/2024 - 03/2024
2	tremelimumabIBA 03/2024 - 08/2023
2	tislelizumabIBA 10/2023 - 06/2019
2	Aromatase InhibitorsIBA 03/2023 - 10/2022
2	Peptides (Polypeptides)IBA 01/2020 - 09/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 09/2012
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2020 - 03/2013
2	CreatinineIBA 10/2019 - 01/2019
2	infigratinibIBA 01/2018 - 05/2013
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 01/2018 - 05/2013
2	VimentinIBA 01/2018 - 11/2007
2	Fulvestrant (Faslodex)FDA Link 02/2015 - 03/2013
2	Everolimus FDA Link 02/2015 - 12/2013
2	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 06/2013 - 04/2013
2	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 08/2010
2	dacomitinibIBA 01/2013 - 09/2012
2	src-Family KinasesIBA 11/2011 - 08/2010
2	AZD 6244IBA 07/2010 - 03/2010
2	Progesterone Receptors (Progesterone Receptor)IBA 09/2009 - 08/2009
2	Capecitabine (Xeloda)FDA Link 12/2008 - 01/2008

Therapy/Procedure

75	Therapeutics 04/2024 - 01/2003
13	Drug Therapy (Chemotherapy) 11/2023 - 10/2007
10	Liver Transplantation 01/2019 - 12/2010
4	Immunotherapy 02/2024 - 01/2021
2	Drug Tapering 12/2020 - 12/2019
2	Transplantation 10/2020 - 10/2016
2	Radiofrequency Ablation 01/2018 - 01/2017